Brexit Q&A: Where Do Notified Body, Authorized Representative Offices Need To Be?
Executive Summary
Medtech regulatory service providers cannot afford to "wait and see" on the final outcome of Brexit. Questions such as the appropriate base of operations to serve device companies looking to sell into the UK and the EU are swirling. So how should the sector be covering its back? Medtech Insight spoke to John Adcock of Advena, a consultancy that serves as an authorized representative, to find out his views.
You may also be interested in...
UK Plans To Implement Medtech Regulations, Keep Them Until At Least Summer 2019, Observers Suggest
The uncertainty over the UK position in Europe, on top of the questions surrounding many aspects of the implementation of the EU’s forthcoming medtech regulations, is making any efforts at planning difficult for many in the medtech sector. But indications are that the UK will be on board the EU medtech ship a while longer.
EU Regulatory Roundup, March 2024: Busy Agenda In Broad Range Of Key Areas
March was an important month for EU medtech regulation with an interesting spread of news relating to the Medical Device and IVD Regulations, the Batteries Regulation, the Artificial Intelligence Act and more.
EU’s Revised Phthalates Guideline Features New Annexes Focused On Alternatives
The effects of phthalates, plasticizers used in many medical devices, on the human endocrine system, have long been debated. But how safe are the alternatives? Updated guidelines give more insight.